Stay updated on GARNET: Anti-PD-1 Antibody Clinical Trial
Sign up to get notified when there's something new on the GARNET: Anti-PD-1 Antibody Clinical Trial page.

Latest updates to the GARNET: Anti-PD-1 Antibody Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has been updated to reflect a new total of 130 study locations, with several principal investigators added, including Charles A. Leath, III and Michael S. Gordon. Additionally, several previously listed locations have been withdrawn, including sites in Phoenix, Atlanta, and Buenos Aires.SummaryDifference15%
- Check78 days agoChange DetectedThe website has updated its clinical trials information, adding new contact details and a revision to version 2.14.0, while removing the previous version 2.13.3 and its associated contact information.SummaryDifference45%
- Check99 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.0%
- Check106 days agoChange DetectedThe website has been updated from version 2.13.0 to 2.13.2, indicating new features or improvements.SummaryDifference0.0%
- Check114 days agoChange DetectedThe website has updated the contact details section for the study, now providing clearer information on who to contact and where the study is taking place, reflecting a revision from v2.12.2 to v2.13.0.SummaryDifference0.5%
- Check121 days agoChange DetectedThe website has been updated to Revision v2.12.2, with previous content related to the safety and efficacy of dostarlimab in various cancer studies removed.SummaryDifference4%
Stay in the know with updates to GARNET: Anti-PD-1 Antibody Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GARNET: Anti-PD-1 Antibody Clinical Trial page.